Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation

Bone Marrow Transplantation

Volumn 41, Issue 8, 2008, Pages 715-720

  Costa, L J ^a   Micallef, I N ^a   Inwards, D J ^a   Johnston, P B ^a   Porrata, L F ^a   Ansell, S M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTHRACYCLINE; CARMUSTINE; COTRIMOXAZOLE; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LEVOFLOXACIN; MELPHALAN; RITUXIMAB;

ADULT; AGED; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BLEEDING; BLOOD TRANSFUSION; CANCER MORTALITY; CANCER RELAPSE; CD34 SELECTION; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; ERYTHROCYTE CONCENTRATE; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK ASSESSMENT; STEM CELL MOBILIZATION; SURVIVAL RATE; SURVIVAL TIME; TIME; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ADULT; AGED; COHORT STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 42549121569     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705967     Document Type: Article

References (35)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909-3918.
2. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
3. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947.
4. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
5. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23 4117-4126.
6. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121-3127.
7. Bonnet C, Fillet G, Mounier N, Ganem G, Molina TJ, Thiéblemont C et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007; 25: 787-792.
8. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-HodgKin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
9. Gutierre M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: An 8-year follow-up study of EPOCH. J Clin Oncol 2000; 18: 3633-3642.
10. Cabanillas F, Hagemeister FB, McLaughlin P, Velasquez WS, Riggs S, Fuller L et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 1987; 5: 407-412.
11. Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117-122.
12. Vellenga E, van Agthoven M, Croockewit AJ, Verdonck LF, Wijermans PJ, van Oers MH et al. Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: The Hovon 22 study. Br J Haematol 2001; 114: 319-326.
13. Vose JM, Sharp G, Chan WC, Nichols C, Loh K, Inwards D et al. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol 2002; 20: 2344-2352.
14. Guglielmi C, Gomez F, Philip T, Hagenbeek A, Martelli M, Sebban C et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 1998; 16 3264-3269.
15. Blay J, Gomez F, Sebban C, Bachelot T, Biron P, Guglielmi C et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: Analysis of the PARMA trial. Parma Group. Blood 1998; 92: 3562-3568.
16. Moskowitz CH, Nimer SD, Glassman JR, Portlock CS, Yahalom J, Straus DJ et al. The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma. Bone Marrow Transplant 1999; 23: 561-567.
17. Lerner RE, Thomas W, Defor TE, Weisdorf DJ, Burns LJ. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission. Biol Blood Marrow Transplant 2007; 13: 486-492.
18. Jabbour E, Peslin N, Arnaud P, Ferme C, Carde P, Vantelon J et al. Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation. Leuk Lymphoma 2005; 46: 861-867.
19. Hamlin PA, Zelenetz AD, Kewalramani T, Qin J, Satagopan JM, Verbel D et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003; 102: 1989-1996.
20. Saez R, Dahlberg S, Appelbaum FR, Hartsock RJ, Lemaistre F, Coltman Jr CA et al. Autologous bone marrow transplantation in adults with non-Hodgkin's lymphoma: A Southwest Oncology Group study. Hematol Oncol 1994; 12: 75-85.
21. Reyes F, Lepage E, Ganem G, Molina TJ, Brice P, Coiffier B et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005; 352: 1197-1205.
22. Vose JM, Anderson JR, Kessinger A, Bierman PJ, Coccia P, Reed EC et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1846-1851.
23. Philip T, Chauvin F, Armitage J, Bron D, Hagenbeek A, Biron P et al. Parma international protocol: Pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood 1991; 77: 1587-1592.
24. Carey PJ, Proctor SJ, Taylor P, Hamilton PJ. Autologous bone marrow transplantation for high-grade lymphoid malignancy using melphalan/ irradiation conditioning without marrow purging or cryopreservation. The Northern Regional Bone Marrow Transplant Group. Blood 1991; 77 1593-1598.
25. Philip T, Biron P, Maraninchi D, Goldstone AH, Herve P, Souillet G et al. Massive chemotherapy with autologous bone marrow transplantation in 50 cases of bad prognosis non-Hodgkin's lymphoma. Br J Haematol 1985; 60: 599-609.
26. Prince HM, Imrie K, Crump M, Stewart AK, Girouard C, Colwill R et al. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: Identification of major prognostic groups. Br J Haematol 1996; 92: 880-889.
27. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
28. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-3849.
29. Gopal AK, Rajendran JG, Petersdorf SH, Maloney DG, Eary JF, Wood BL et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002; 99: 3158-3162.
30. Smith SD, Bolwell BJ, Rybicki LA, Brown S, Dean R, Kalaycio M et al. Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Transplant 2007; 40: 239-243.
31. Buadi FK, Micallef IN, Ansell SM, Porrata LF, Dispenzieri A, Elliot MA et al. Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 2006; 37: 1017-1022.
32. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857-1861.
33. Shimoni A, Zwas ST, Oksman Y, Hardan I, Shem-Tov N, Yerushalmi R et al. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. Exp Hematol 2007; 35: 534-540.
34. Nademanee A, Forman S, Molina A, Fung H, Smith D, Dagis A et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etopo-side and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005; 106: 2896-2902.
35. Press OW, Eary JF, Gooley T, Gopal AK, Liu S, Rajendran JG et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000; 96: 2934-2942.